Dialysexentrum Elsenfeld
Elsenfeld, 63820, Germany
NCT Number: NCT02377622
The study investigates the performance of a new dialyzer (Theranova 400) containing a membrane with increased pore sizes. The performance will be determined by the removal of middle molecules (with different molecular size) from the blood compartment. Two different Theranova 400 prototypes (AA and BB) operated in hemodialysis mode will be compared with a Cordiax Fx-80 dialyzer, operated in hemodialysis mode, and with a Cordiax Fx-800, operated in high volume hemodiafiltration mode. Safety events and albumin loss into the dialysate will be monitored
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
Elsenfeld, 63820, Germany
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: Five (5) hours ( for each mid-week dialysis session)
Blood and dialysate
Time frame: Five (5) hours (for each mid-week dialysis session)
Dialysate
Time frame: Average 60 days (continuously, from signature of informed consent form until 1 week after last hemodialysis session with an experimental or active comparator product)
All adverse events and device deficiencies will be recorded
Time frame: Five (5) hours (for each mid-week dialysis session)
Blood and dialysate
Time frame: Five (5) hours ( for each mid-week dialysis session)
Blood
Vantive Health LLC
Industry
Comparison of the Clinical Performance of 2 THERANOVA 400 Dialyzer Prototypes in HD With a High-Flux Dialyzer in HD and a High-Flux Dialyzer in hvHDF - A Pilot Study
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06515899
Chronic Disease, Disease Attributes
Stevenage, Hertfordshire, United Kingdom
View Trial DetailsNCT03719339
Acute Cellular Graft Rejection, Antibody-mediated Rejection
La Jolla, California, United States
View Trial DetailsNCT04817774
Chronic Disease, Disease Attributes
Leuven, Belgium
View Trial DetailsNCT02984124
Chronic Disease, Disease Attributes
Chapel Hill, North Carolina, United States
View Trial Details